Siddharth Singh1, Antonio Facciorusso2, Parambir S Dulai3, Vipul Jairath4, William J Sandborn3. 1. Division of Gastroenterology, University of California San Diego, La Jolla, California; Division of Biomedical Informatics, Department of Medicine, University of California San Diego, La Jolla, California. Electronic address: sis040@ucsd.edu. 2. Gastroenterology Unit, Department of Medical Sciences, University of Foggia, Foggia, Italy. 3. Division of Gastroenterology, University of California San Diego, La Jolla, California. 4. Division of Gastroenterology, Department of Medicine, University Hospital, Ontario, Canada; Division of Epidemiology and Biostatistics, Western University, London, Ontario, Canada.
Abstract
BACKGROUND & AIMS: We performed a systematic review and meta-analysis to evaluate the comparative risk of serious infections with tumor necrosis factor (TNF) antagonists, non-TNF targeted biologics, tofacitinib, and immunosuppressive agents in patients with inflammatory bowel diseases (IBDs). METHODS: In a systematic search of publications, through March 18, 2018, we identified 15 observational studies (>500 person-years) of patients with IBD treated with TNF antagonists, non-TNF targeted biologics, tofacitinib, and/or immunosuppressive agents (thiopurines, methotrexate) that reported risk of serious infections. Only studies with active comparators were included, to allow appropriate comparative synthesis. We performed random-effects meta-analysis and estimated relative risk (RR) and 95% CIs. RESULTS: Compared with anti-TNF monotherapy, risk of serious infection increased with the combination of anti-TNF and an immunosuppressive agent (in 6 cohorts: RR, 1.19; 95% CI, 1.03-1.37), with anti-TNF and a corticosteroid (in 4 cohorts: RR, 1.64; 95% CI, 1.33-2.03), or with all 3 drugs (in 2 cohorts: RR, 1.35; 95% CI, 1.04-1.77); there was minimal heterogeneity among studies. In contrast, monotherapy with an immunosuppressive agent was associated with a lower risk of serious infections than monotherapy with a TNF antagonist (7 cohorts: RR, 0.61; 95% CI 0.44-0.84) or a TNF antagonist with an immunosuppressive agent (2 cohorts: RR, 0.56; 95% CI, 0.39-0.81). Infliximab-based therapy was associated with a lower risk of serious infections compared with adalimumab-based therapy in patients with ulcerative colitis (4 cohorts: RR, 0.57; 95% CI, 0.33-0.97), but not Crohn's disease (4 cohorts: RR, 0.91; 95% CI, 0.49-1.70). Few data were available on the comparative safety of biologic agents that do not inhibit TNF and tofacitinib. CONCLUSIONS: Combination therapies for IBD that include TNF antagonists, especially with corticosteroids, are associated with a higher risk of serious infection, whereas monotherapy with an immunosuppressive agent is associated with a lower risk, compared with monotherapy with a TNF antagonist. Studies are needed to evaluate the comparative safety of non-TNF targeted biologics and small molecules for treatment of IBD.
BACKGROUND & AIMS: We performed a systematic review and meta-analysis to evaluate the comparative risk of serious infections with tumor necrosis factor (TNF) antagonists, non-TNF targeted biologics, tofacitinib, and immunosuppressive agents in patients with inflammatory bowel diseases (IBDs). METHODS: In a systematic search of publications, through March 18, 2018, we identified 15 observational studies (>500 person-years) of patients with IBD treated with TNF antagonists, non-TNF targeted biologics, tofacitinib, and/or immunosuppressive agents (thiopurines, methotrexate) that reported risk of serious infections. Only studies with active comparators were included, to allow appropriate comparative synthesis. We performed random-effects meta-analysis and estimated relative risk (RR) and 95% CIs. RESULTS: Compared with anti-TNF monotherapy, risk of serious infection increased with the combination of anti-TNF and an immunosuppressive agent (in 6 cohorts: RR, 1.19; 95% CI, 1.03-1.37), with anti-TNF and a corticosteroid (in 4 cohorts: RR, 1.64; 95% CI, 1.33-2.03), or with all 3 drugs (in 2 cohorts: RR, 1.35; 95% CI, 1.04-1.77); there was minimal heterogeneity among studies. In contrast, monotherapy with an immunosuppressive agent was associated with a lower risk of serious infections than monotherapy with a TNF antagonist (7 cohorts: RR, 0.61; 95% CI 0.44-0.84) or a TNF antagonist with an immunosuppressive agent (2 cohorts: RR, 0.56; 95% CI, 0.39-0.81). Infliximab-based therapy was associated with a lower risk of serious infections compared with adalimumab-based therapy in patients with ulcerative colitis (4 cohorts: RR, 0.57; 95% CI, 0.33-0.97), but not Crohn's disease (4 cohorts: RR, 0.91; 95% CI, 0.49-1.70). Few data were available on the comparative safety of biologic agents that do not inhibit TNF and tofacitinib. CONCLUSIONS: Combination therapies for IBD that include TNF antagonists, especially with corticosteroids, are associated with a higher risk of serious infection, whereas monotherapy with an immunosuppressive agent is associated with a lower risk, compared with monotherapy with a TNF antagonist. Studies are needed to evaluate the comparative safety of non-TNF targeted biologics and small molecules for treatment of IBD.
Authors: Joseph Meserve; Satimai Aniwan; Jenna L Koliani-Pace; Preeti Shashi; Aaron Weiss; David Faleck; Adam Winters; Shreva Chablaney; Gursimran Kochhar; Brigid S Boland; Siddharth Singh; Robert Hirten; Eugenia Shmidt; Justin G Hartke; Prianka Chilukuri; Matthew Bohm; Sashidhar Varma Sagi; Monika Fischer; Dana Lukin; David Hudesman; Shannon Chang; Youran Gao; Keith Sultan; Arun Swaminath; Nitin Gupta; Sunanda Kane; Edward V Loftus; Bo Shen; Bruce E Sands; Jean-Frederic Colombel; Corey A Siegel; William J Sandborn; Parambir S Dulai Journal: Clin Gastroenterol Hepatol Date: 2018-09-27 Impact factor: 11.382
Authors: Mark T Osterman; William J Sandborn; Jean-Frederic Colombel; Laurent Peyrin-Biroulet; Anne M Robinson; Qian Zhou; James D Lewis Journal: Am J Gastroenterol Date: 2016-09-27 Impact factor: 10.864
Authors: Brian G Feagan; John W D McDonald; Remo Panaccione; Robert A Enns; Charles N Bernstein; Terry P Ponich; Raymond Bourdages; Donald G Macintosh; Chrystian Dallaire; Albert Cohen; Richard N Fedorak; Pierre Paré; Alain Bitton; Fred Saibil; Frank Anderson; Allan Donner; Cindy J Wong; Guangyong Zou; Margaret K Vandervoort; Marybeth Hopkins; Gordon R Greenberg Journal: Gastroenterology Date: 2013-11-21 Impact factor: 22.682
Authors: Reena Khanna; Brian Bressler; Barrett G Levesque; Guangyong Zou; Larry W Stitt; Gordon R Greenberg; Remo Panaccione; Alain Bitton; Pierre Paré; Séverine Vermeire; Geert D'Haens; Donald MacIntosh; William J Sandborn; Allan Donner; Margaret K Vandervoort; Joan C Morris; Brian G Feagan Journal: Lancet Date: 2015-09-03 Impact factor: 79.321
Authors: Geert DʼHaens; Walter Reinisch; Remo Panaccione; Jack Satsangi; Joel Petersson; Mareike Bereswill; Dilek Arikan; Eva Perotti; Anne M Robinson; Jasmina Kalabic; Gabriela Alperovich; Roopal Thakkar; Edward V Loftus Journal: Am J Gastroenterol Date: 2018-06-05 Impact factor: 10.864
Authors: Marius Vögelin; Luc Biedermann; Pascal Frei; Stephan R Vavricka; Sylvie Scharl; Jonas Zeitz; Michael C Sulz; Michael Fried; Gerhard Rogler; Michael Scharl Journal: PLoS One Date: 2016-05-23 Impact factor: 3.240
Authors: Akbar K Waljee; Wyndy L Wiitala; Shail Govani; Ryan Stidham; Sameer Saini; Jason Hou; Linda A Feagins; Nabeel Khan; Chester B Good; Sandeep Vijan; Peter D R Higgins Journal: PLoS One Date: 2016-06-23 Impact factor: 3.240
Authors: John George; Siddharth Singh; Parambir S Dulai; Christopher Ma; Tran Nguyen; Brian G Feagan; William J Sandborn; Vipul Jairath Journal: Inflamm Bowel Dis Date: 2020-03-04 Impact factor: 5.325
Authors: Siddharth Singh; Herbert C Heien; Lindsey Sangaralingham; Nilay D Shah; Jennifer C Lai; William J Sandborn; Alison A Moore Journal: Inflamm Bowel Dis Date: 2021-10-18 Impact factor: 5.325
Authors: Maryam Alkhatry; Ahmad Al-Rifai; Vito Annese; Filippos Georgopoulos; Ahmad N Jazzar; Ahmed M Khassouan; Zaher Koutoubi; Rahul Nathwani; Mazen S Taha; Jimmy K Limdi Journal: World J Gastroenterol Date: 2020-11-21 Impact factor: 5.742